Abstract:Background: Lung cancer results in more than 131,000 deaths per year with estimated 236,000 new cases in 2021 in the United States. About 85% of lung cancers are non-small cell lung cancer (NSCLC). TP53 is an important tumor-suppressor and about 50% of human lung NSCLCs contain a mutant TP53. Targeting of mutant p53 is very limited due to the lack of drugs. PRIMA-1 is a first in class anti-mutant TP53 molecule with the ability to induce apoptosis by restoring the wild-type function of TP53 through covalently binding and modifying thiol groups in the central domain of the mutated protein. Recently, the FDA granted breakthrough therapy designation to the PRIMA-1 methylated analog, APR-246 in combination with azacytidine for the treatment of patients with myelodysplastic syndromes and a TP53 mutation. The major setback of targeted therapy today continues to be resistance. Herein, we report our findings related to resistance to PRIMA-1 targeted therapy in spontaneous P53 mutant driven NSCLC. Methods: We have previously reported the generation of a line of transgenic mice with a human mutant p53(273H) expressed in a lung-specific manner. Human mutant TP53 expression was regulated under the transcriptional control of the human surfactant protein C (SP-C) promoter. After the age of 12 months, the mice developed spontaneous lung adenocarcinomas. We treated SPC-p53-273H lung tumor mice via intraperitoneal injection (i.p) with PRIMA-1 at a dose of 100 mg/kg in 0.2 mL PBS every other day for two weeks. The tumors were identified using micro-computed tomography (micro-CT) system and pre-and post-treatment diameters were estimated based on the CT image. K-ras status was analyzed by PCR-based Sanger sequencing. Results: Of the 10 lung tumor-bearing mice treated with PRIMA-1, micro-CT derived sum of the largest diameters indicated that six mice (60%) experienced tumor volume reductions whereas four mice experienced tumor volume increase. Sequencing analysis showed five tumors contained K-ras mutations (two p.G12D, one p.G12F, one p.G12V and one p.Q61L). On average, lung tumor diameter had a 31% reduction post-treatment of PRIMA-1 for the lung tumors containing wild-type K-ras gene. Whereas it increased 18% on the average post-treatment of PRIMA-1 for the lung tumors containing a mutant K-ras gene. There is a significant difference statistically (p = 0.016) in the response to the treatment of PRIMA-1 between the mutant K-ras cohort and the wild-type K-ras cohort. Conclusion: PRIMA 1 therapy results in antitumor activity against P53 mutant lung tumors. However, the presence of K-ras co-mutation is a significant resistance factor. Combination of APR-246 and K-ras inhibitor therapy would be needed to overcome this resistance. Citation Format: David T. Costa, Shaylyn Grier, Melanie Perez, Li Gao, Miguel A. Villalona-Calero, Wenrui Duan. Kras Co-mutations lead to resistance to mutant TP53 targeted therapy in mouse models of spontaneous non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 6184.

Human Mutant P53 Lung Cancer Cells Respond Differently to PRIMA-1 Induced Apoptosis

Inhibition of nonsense-mediated decay rescues p53/ isoform expression and activates the p53 pathway in and select-mutant cancers

PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.

PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK

Abstract 6184: Kras Co-mutations lead to resistance to mutant TP53 targeted therapy in mouse models of spontaneous non-small cell lung cancer

Integrated High Throughput Analysis Identifies GSK3 As a Crucial Determinant of P53-Mediated Apoptosis in Lung Cancer Cells

Small-Molecule Modulators Of P53 Family Signaling And Antitumor Effects In P53-Deficient Human Colon Tumor Xenografts

A Small Molecule That Disrupts Mdm2-p53 Binding Activates P53, Induces Apoptosis, and Sensitizes Lung Cancer Cells to Chemotherapy

PRIMA-1, a Mutant P53 Reactivator, Restores the Sensitivity of TP53 Mutant-Type Thyroid Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A.

Therapeutic Restoring P53 Function with Small Molecule for Oncogene-Driven Non-Small Cell Lung Cancer by Targeting Serine 392 Phosphorylation.

PRAP1 is a novel executor of p53-dependent mechanisms in cell survival after DNA damage

Global Genechip Profiling to Identify Genes Responsive to P53-Induced Growth Arrest and Apoptosis in Human Lung Carcinoma Cells

Inhibition of AKT/FoxO3a signaling induced PUMA expression in response to p53-independent cytotoxic effects of H1: A derivative of tetrandrine.

Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53

The Tumor Suppressor, P53, Contributes to Radiosensitivity of Lung Cancer Cells by Regulating Autophagy and Apoptosis.

APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy

P-Glycoprotein-Independent Apoptosis Induction By A Novel Synthetic Compound, Mmpt [5-[(4-Methylphenyl)Methylene]-2-(Phenylamino)-4 (5h)-Thiazolone]

Oncogenic Mutant p53 Sensitizes Non-Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress-Dependent Induction of Mitochondrial Apoptosis

Pyrimidine Triones as Potential Activators of p53 Mutants

Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA

Exogenous P53 Upregulated Modulator of Apoptosis (PUMA) Decreases Growth of Lung Cancer A549 Cells